Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.American journal of hypertension · 2025
   Trial
2. Aldosterone in Chronic Kidney Disease.Biomedicines · 2025
   Review
3. Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease.International journal of molecular sciences · 2024
   Review
4. The Effect of Aldosterone on Cardiorenal and Metabolic Systems.International journal of molecular sciences · 2023
   Review
5. Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients.ESC heart failure · 2020
   Observational
6. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes.BMJ open diabetes research & care · 2020
   Article
7. Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.Frontiers in pharmacology · 2020
   Article

Corrections and comments

• Comment on
  Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as